Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.

Cancer chemotherapy and pharmacology - 1 Oct 2017

Srinivasan Gayathri, Sidhu Gurjit Singh, Williamson Elizabeth A, Jaiswal Aruna S, Najmunnisa Nasreen, Wilcoxen Keith, Jones Dennie, George Thomas J, Hromas Robert

Abstract excerpt

Malignant pleural mesotheliomas (MPM) are most often surgically unresectable, and they respond poorly to current chemotherapy and radiation therapy. Between 23 and 64% of malignant pleural mesothelioma have somatic inactivating mutations in the BAP1 gene. BAP1 is a homologous recombination (HR) DNA repair component found in the BRCA1/BARD1 complex. Similar to BRCA1/2 deficient cancers, mutation in the BAP1 gene...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mesothelioma
Share to Mesothelioma, Malignant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indazoles

Share to Phthalazines

Share to Pleural Neoplasms

Share to Poly (ADP-Ribose) Polymerase-1

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Synthetic Lethal Mutations

Source

Open in PubMed Open full text

Identifiers

PMID: 28756516
DOI: 10.1007/s00280-017-3401-y
PMCID: PMC5608777

Genes

PARP1
BAP1
BRCA1
BARD1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Synthetic lethality in malignant pleural mesothelioma with PARP1 inhibition.PMID 28756516Read ↗

Functional Genomic Screen in Mesothelioma Reveals that Loss of Function of BRCA1-Associated Protein 1 Induces Chemoresistance to Ribonucleotide Reductase InhibitionSemantic proximity Read ↗

A Prospective Phase II Single-arm Study of Niraparib Plus Dostarlimab in Patients With Advanced Non-small-cell Lung Cancer and/or Malignant Pleural Mesothelioma, Positive for PD-L1 Expression and Germline or Somatic Mutations in the DNA Repair Genes: Rationale and Study Design.Semantic proximity Read ↗

Phase 2 Study of Olaparib in Malignant Mesothelioma and Correlation of Efficacy With Germline or Somatic Mutations in BAP1 GeneSemantic proximity Read ↗

Gene expression profiling of homologous recombination repair pathway indicates susceptibility for olaparib treatment in malignant pleural mesothelioma in vitroSemantic proximity Read ↗

Genome-wide silencing screen in mesothelioma cells reveals that loss of function of BAP1 induces chemoresistance to ribonucleotide reductase inhibition: implication for therapySemantic proximity Read ↗

Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural MesotheliomaSemantic proximity Read ↗

Niraparib plus Dostarlimab in Pleural Mesothelioma or Non-Small Cell Lung Cancer Harboring HRR Mutations: Interim Results of the UNITO-001 Phase II Prospective Trial.Semantic proximity Read ↗

Drug-Driven Synthetic Lethality: Bypassing Tumor Cell Genetics with a Combination of AsiDNA and PARP InhibitorsSemantic proximity Read ↗

ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 InhibitorsSemantic proximity Read ↗

Synthetic lethality: exploiting the addiction of cancer to DNA repair.Semantic proximity Read ↗

MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesotheliomaSemantic proximity Read ↗

Embracing synthetic lethality of novel anticancer therapies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.